Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.[1][2]
It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).[3][4]
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.